News
| 5 min read
Regulatory science is increasingly relying on modeling, simulation, and AI tools to accelerate drug development while maintaining safety and efficacy.
| 10 min read
Strategies including parasite-based vaccines, mosquito-transmission blockers, and antibody drugs are promising new ways to target the disease.
| 3 min read
Blood tests can’t diagnose Alzheimer’s disease yet, but one is already approved and more are on the way.
| 4 min read
Vertex-Enlaza autoimmune drugs, DNA-wrapped CRISPR, HHS staff demand Kennedy’s resignation, and more lead the news this week.
| 4 min read
Short-acting psychedelics like bretisilocin could offer rapid, lasting relief for patients with major depressive disorder.
| 6 min read
Macrophage-based therapies for liver cirrhosis are entering clinical trials, but key challenges remain before they become a viable treatment.
| 2 min read
A new transformer-based model links tumor morphology with multiple genetic alterations, offering faster diagnostics and insights to guide precision oncology.
| 3 min read
Oral GLP-1 data, srRNA therapies, and decentralized CAR T led drug discovery this week.
| 9 min read
Two ongoing Phase 1 trials will produce the first human data on these potentially revolutionary cancer drugs.
| 5 min read
Animal and cell culture models have fallen short in kidney disease research. Kidney organoids may offer a better way forward.
| 2 min read
Researchers showed that in rodent models, a glia-produced molecule could regulate weight loss and glucose metabolism without gastrointestinal symptoms.
| 4 min read
Boston meeting brought scientists and industry leaders together to discuss disease mechanisms, advanced models, and research funding pressures.
